Patients with the rs7270101 AA genotype and chronic hepatitis C may have an increased risk of anemia when treated with peg interferon alfa-2b and ribavirin as compared to patients with the AC and CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may influence the risk of anemia.